The Board of Directors of Merck & Co., Inc. (NYSE:MRK) authorized a share repurchase program on May 1, 2013. Under the program, the company will repurchase up to $15 billion worth of its shares. The repurchases will be made in the open-market, block transactions on or off an exchange, or in privately negotiated transactions. The shares will be repurchased for its treasury. The company expects to finance approximately $7.5 billion repurchases through a combination of ... debt issuance and operating cash flows. The program reinforces its commitment to delivering increased value to the shareholders and the Board's confidence in the long-term growth strategy and future performance. The repurchases worth approximately $7.5 billion will take place over the next 12 months with the remainder to be repurchased over time with no time limit.
Read More

Cerecor, Inc. acquired rights to NR2B receptor antagonist from Merck & Co. Inc. (NYSE:MRK) on April 19, 2013. The consideration for the transaction includes milestone payments and royalties consistent with clinical stage licenses in neuroscience. Michelle Avery of MacDougall Biomedical Communications acted as public relations advisor in the transaction.

Hawaii Biotech, Inc. acquired patent family to West Nile virus vaccine technology from Merck & Co. Inc. (NYSE:MRK) on April 11, 2013.

Cerecor, Inc. acquired worldwide rights to COMT Inhibitors from Merck & Co. Inc. (NYSE:MRK) on March 20, 2013.

Sponsored Financial Commentaries

To contact MERCK & CO. INC., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.